CR10111A - Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido - Google Patents
Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituidoInfo
- Publication number
- CR10111A CR10111A CR10111A CR10111A CR10111A CR 10111 A CR10111 A CR 10111A CR 10111 A CR10111 A CR 10111A CR 10111 A CR10111 A CR 10111A CR 10111 A CR10111 A CR 10111A
- Authority
- CR
- Costa Rica
- Prior art keywords
- heteroaril
- canabinoid
- phenil
- pirazol
- modular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta invención está dirigida a un compuesto modulador de canabinoide 5-heteroaril-1-pirazol sustituido de la fórmula (I): o una forma del mismo, y métodos para usarse en el tratamiento, alivio o prevención de un síndrome, trastorno o enfermedad mediada por receptor de canabinoide.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73912905P | 2005-11-23 | 2005-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10111A true CR10111A (es) | 2009-01-14 |
Family
ID=37983697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10111A CR10111A (es) | 2005-11-23 | 2008-06-23 | Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070117858A1 (es) |
EP (1) | EP1966194A2 (es) |
JP (1) | JP2009517388A (es) |
KR (1) | KR20080070078A (es) |
CN (1) | CN101360741A (es) |
AU (1) | AU2006318661A1 (es) |
BR (1) | BRPI0618856A2 (es) |
CA (1) | CA2630699A1 (es) |
CR (1) | CR10111A (es) |
EA (1) | EA200801399A1 (es) |
EC (1) | ECSP088468A (es) |
IL (1) | IL191585A0 (es) |
MX (1) | MX2008006739A (es) |
NO (1) | NO20082505L (es) |
WO (1) | WO2007061948A2 (es) |
ZA (1) | ZA200805405B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853205B2 (en) | 2005-01-10 | 2014-10-07 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
WO2010104488A1 (en) * | 2009-02-19 | 2010-09-16 | University Of Connecticut | Novel hetero pyrrole analogs acting on cannapinoid receptors |
GB0625196D0 (en) * | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
US7943653B2 (en) * | 2007-08-13 | 2011-05-17 | Janssen Pharmaceutica N.V. | Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators |
US10053444B2 (en) | 2009-02-19 | 2018-08-21 | University Of Connecticut | Cannabinergic nitrate esters and related analogs |
AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
BR112019013493A2 (pt) * | 2017-01-10 | 2020-01-07 | National Health Research Institutes | Compostos heterocíclicos e seus usos |
CA3125847A1 (en) | 2020-07-27 | 2022-01-27 | Makscientific, Llc | Process for making biologically active compounds and intermediates thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2948718A (en) * | 1960-08-09 | New n-heterocyclic compounds | ||
US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
GR68380B (es) * | 1979-06-01 | 1981-12-28 | Wellcome Found | |
LU83729A1 (fr) * | 1981-11-04 | 1983-09-01 | Galephar | Sels d'acide valproique,leur preparation et leur utilisation |
US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US5242940A (en) * | 1987-05-29 | 1993-09-07 | Ortho Pharmaceutical Corporation | Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same |
US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
ITMI20041032A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
US20060025448A1 (en) * | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
-
2006
- 2006-11-16 US US11/560,431 patent/US20070117858A1/en not_active Abandoned
- 2006-11-17 EA EA200801399A patent/EA200801399A1/ru unknown
- 2006-11-17 CA CA002630699A patent/CA2630699A1/en not_active Abandoned
- 2006-11-17 MX MX2008006739A patent/MX2008006739A/es unknown
- 2006-11-17 JP JP2008542393A patent/JP2009517388A/ja not_active Withdrawn
- 2006-11-17 EP EP06838057A patent/EP1966194A2/en not_active Withdrawn
- 2006-11-17 AU AU2006318661A patent/AU2006318661A1/en not_active Abandoned
- 2006-11-17 CN CNA2006800514935A patent/CN101360741A/zh active Pending
- 2006-11-17 WO PCT/US2006/044890 patent/WO2007061948A2/en active Application Filing
- 2006-11-17 KR KR1020087015034A patent/KR20080070078A/ko not_active Application Discontinuation
- 2006-11-17 BR BRPI0618856-7A patent/BRPI0618856A2/pt not_active Application Discontinuation
-
2008
- 2008-05-20 IL IL191585A patent/IL191585A0/en unknown
- 2008-05-23 EC EC2008008468A patent/ECSP088468A/es unknown
- 2008-06-05 NO NO20082505A patent/NO20082505L/no not_active Application Discontinuation
- 2008-06-20 ZA ZA200805405A patent/ZA200805405B/xx unknown
- 2008-06-23 CR CR10111A patent/CR10111A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2630699A1 (en) | 2007-05-31 |
EA200801399A1 (ru) | 2009-12-30 |
BRPI0618856A2 (pt) | 2011-09-13 |
ZA200805405B (en) | 2009-11-25 |
KR20080070078A (ko) | 2008-07-29 |
MX2008006739A (es) | 2009-03-04 |
EP1966194A2 (en) | 2008-09-10 |
WO2007061948A2 (en) | 2007-05-31 |
US20070117858A1 (en) | 2007-05-24 |
AU2006318661A1 (en) | 2007-05-31 |
JP2009517388A (ja) | 2009-04-30 |
WO2007061948A3 (en) | 2007-07-12 |
IL191585A0 (en) | 2008-12-29 |
CN101360741A (zh) | 2009-02-04 |
NO20082505L (no) | 2008-08-12 |
ECSP088468A (es) | 2008-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10111A (es) | Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido | |
CY1118523T1 (el) | Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus | |
ECSP066877A (es) | Moduladores canabinoides de tetrahidro-indazol | |
PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
GT200500158A (es) | Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa | |
CL2011000101A1 (es) | Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas. | |
ECSP088315A (es) | Moduladores de hexahidro-ciclooctil pirazol cannabinoide | |
DOP2009000243A (es) | Inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cancer | |
CL2008001705A1 (es) | Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3. | |
ECSP10010409A (es) | INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 | |
RS53124B (en) | USE OF BETANECOL FOR THE TREATMENT OF XEROSOMOMY | |
CR11099A (es) | Uso de compuestos inhibidores de quinaxolina de p13k-alfa para el tratamiento del cancer | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
ECSP088316A (es) | Moduladores sustituidos de 3-amido-tetrahidro-indazolil cannabinoide | |
PA8850801A1 (es) | Compuestos útiles para inhibir chk1 | |
CL2007002382A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel. | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
AR061446A1 (es) | Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico | |
CL2011000165A1 (es) | Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
CY1114760T1 (el) | Θεραπευτικη αγωγη αθηροσκληρωσης | |
EA200702336A1 (ru) | ПРИМЕНЕНИЕ 24-норУДХК | |
ECSP088314A (es) | Moduladores de cannabinoides hexahidro-cicloheptapirazol | |
CR9057A (es) | Compuestos aromaticos de arilsulfonilmetil o arilsilfonamida sustituida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 | |
ATE481395T1 (de) | Cyclohexylderivate | |
EA200971067A1 (ru) | Триазолиламинопиримидиновые соединения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |